Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.
Morgan Meisner, PhD
Advertisement
Articles by Morgan Meisner, PhD
Advertisement
Latest Updated Articles
Triplet Targeted Therapy May Signal a New Standard in Metastatic CRCPublished: July 17th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
5